Bioheng Therapeutics is a clinical-stage company focused on allogeneic "off-the-shelf" universal CAR-T therapies. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy platforms and products to address some of the most challenging unmet needs.
In February 2025, our CD7-targeted UCAR-T, CTD402, received Investigational New Drug (IND) approval from the U.S. FDA for the treatment of T-ALL/LBL.This product is based on Bioheng's novel and proprietary UCAR-T technology platform - ANSWER®. We are progressing the global clinical trial for this promising pipeline.
Built upon our ANSWER® platform, we are actively developing multiple UCAR-T pipelines. These programs have demonstrated robust and extended allogeneic CAR-T persistence, showing strong potential in both oncology and autoimmune indications.
We are always striving to meet these unmet needs.
Company Details
- Employees
- 16
- Founded
- -
- Address
- New Jersey, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.bioheng.com
- Keywords
- 细胞治疗 and 生物科技.
- HQ
- New Jersey
Bioheng Therapeutics Questions
Bioheng Therapeutics's website is http://www.bioheng.com
Bioheng Therapeutics's LinkedIn profile is https://www.linkedin.com/company/bioheng-therapeutics-co-ltd
Bioheng Therapeutics has
16 employees.
View email and phone details for 16
employees at Bioheng Therapeutics.
Bioheng Therapeutics's industry is
Biotechnology Research
Bioheng Therapeutics's top competitors are
Cabaletta Bio,
Alivex Biotech,
Actitrexx Gmbh,
Riva Therapeutics,
Latigo Biotherapeutics, Inc.,
Luxa Biotechnology Llc,
Kyverna Therapeutics,
Arcellx,
Jacobio Pharma,
Acepodia.
Bioheng Therapeutics's categories are Biotechnology Research
Bioheng Therapeutics's founding year is 2017
